Bumetanide analog(NeuroPro Therapeutics, Inc.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Bumetanide analog(NeuroPro Therapeutics, Inc.) Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 18 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Bumetanide analog(NeuroPro Therapeutics, Inc.) can convert its Small molecule drug profile and NKCC2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Bumetanide analog(NeuroPro Therapeutics, Inc.) (query alias: Bumetanide analog(NeuroPro Therapeutics, Inc.)) |
|---|---|
| Modality / target | Small molecule drug; NKCC2; NKCC2 inhibitors |
| Highest global status | Phase 2 |
| Originator | NeuroPro Therapeutics, Inc. |
| Active developers | NeuroPro Therapeutics, Inc. |
The MCP disease footprint includes Epilepsy, Generalized, Seizures, Epilepsy, Reflex. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| CTR20263013 | Not Applicable | Active, not recruiting | 38 | Primary endpoint not disclosed in English source |
| CTR20262704 | Not Applicable | Completed | 42 | Primary endpoint not disclosed in English source |
| CTR20262385 | Not Applicable | Active, not recruiting | 36 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Ultra High Dose Diuretic Strategy for Management of Acute Decompensated Heart Failure - A Randomized, Double-Blind Pilot Trial
Phase 2; n=20; evaluation: Not stated in English source. Reported fields: Urine Output(Mean) = 5283 mL ; Urine Output(Mean) = 2819 mL
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
Phase 4; n=107; evaluation: Not stated in English source. Reported fields: Mortality, Days in Hospital & Decongestion = 54.68 % wins ; Mortality, Days in Hospital & Decongestion = 44.16 % wins
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. A 6-month Randomised, Double-blind, Placebo Controlled Multicentre Parallel Group Study to Evaluate Efficacy and Safety of Bumetanide 0.5mg Twice a Day Followed by an Open Label Active 6-month Treatment Period With Bumetanide (0.5mg Twice a Day) and a 6 Weeks Discontinuation Period After Treatment Stop.
Phase 3; n=211; evaluation: Not stated in English source. Reported fields: Reported during the double-blind period (Week 0 - 26) = 103 Pts ; Reported during the double-blind period (Week 0 - 26) = 96 Pts
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Bumetanide analog(NeuroPro Therapeutics, Inc.) addresses Epilepsy, Generalized, Seizures, Epilepsy, Reflex. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 2 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-03-03 | Esperion closes deal for Corstasis Therapeutics’ Enbumyst and CVD franchise | Approved | US$75.0M upfront; US$180.0M milestones |
| 2017-03-14 | Servier and Neurochlore announced the signing of an exclusive licensing agreement to develop and market bumetanide in paediatric autism in Europe | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-18. Counts and status fields may change as source records update.
